




Department  
of Health &  
Social Care

# **DHSC Perspectives on WHA 75.8 implementation**

**Dr Mary De Silva, Deputy Chief Scientific Adviser, UK Department of Health and Social Care**

# The resolution outlines a package of actions for Member States, non-State actors and the WHO to enable well-designed and implemented trials globally

All actors have distinct and complementary roles to play in implementation. The WHO's guidance will provide a helpful roadmap.



## New WHO guidance marks a great opportunity to make existing initiatives more than the sum of their parts

Theme	Relevant Initiative
Enhance clinical trial capability	<b>CIOMS</b> report on clinical research in resource-limited settings, <b>TDR</b> activity to map existing clinical trial networks and infrastructures.
Strengthen international collaboration and coordination	<p><b>Coordinating funding:</b> the Global Research Collaboration for Infectious Diseases (<b>GloPID-R</b>); regional initiatives such as the European and Developing Countries Clinical Trial Partnership (<b>EDCTP</b>).</p> <p><b>Promoting collaboration:</b> bespoke international networks operating on regional footprints, such as <b>ECRAID</b>, <b>ECRIN</b> in Europe.</p>
Improving Standards	<b>ICH E6</b> Good Clinical Practice; Wellcome Trust's <b>Good Clinical Trials Collaborative</b> guidance.
Streamline regulatory and ethical processes	International Coalition of Medicines Regulatory Authorities ( <b>ICMRA</b> ), regional networks such as <b>AVAREF</b> .


Much is underway, however this is **no clear understanding of the current gaps at an ecosystem level**, across and within different global regions, or the evidence-based roles of different actors in ecosystem strengthening.

WHO has a role to play in helping us understand current capacity and the roles of actors in strengthening.



# GloPID-R are working to support implementation of WHA75.8

- **33 Member and 7 Observer Organisations**, consisting of public and philanthropic clinical research funders.
- GloPID-R have launched a **new report with recommendations to support coordinated approaches to clinical trial funding**, aligned with WHA75.8 themes.
- **This forum provides a vehicle to support Member State implementation** of coordinated approaches to clinical trial funding.



GloPID-R, [GloPID-R Funders Living Roadmap for Clinical Trial Coordination](#), 2023




# Work is required in many areas, particularly understanding the infrastructure required to pivot during a pandemic

- 1) **Understanding and developing the required pre-existing infrastructure globally** to enable effective and coordinated clinical trial responses to pandemic threats, such as clinical trial networks and standing trial platforms.
- 2) **Understanding the mechanisms required to pivot routine clinical trial capacity** across the global ecosystem to trigger effective pandemic response.
- 3) **Understanding the roles of all actors in coordination** and facilitating high quality research more readily through trials.



# To support this, the UK is chairing a new international Ministry of Health forum to understand MoH roles as part of the solution

- 8 member countries across global regions. Membership is open to all Member States wishing to engage.
- Focused on developing policy solutions to deliver the actions requested of WHO Member States in the resolution.
- WHO observer membership to promote alignment with the guidance development and WHO public consultation findings.
- Particular focus on how Ministries of Health can best support strong trial networks and multi-country trials.



# The UK remains committed to strengthening clinical trials in collaboration with international partners

- We encourage Member States to join existing initiatives to strengthen clinical trials (such as GloPID-R, ICMRA) and engage through other existing multilateral partnerships and organisations.
- We are happy to discuss membership to the clinical trials Group of Friends with interested Member States.
- We look forward to continued engagement with WHO, Member States and non-State actors to turn WHA75.8 from vision to reality.

